SPRY ARS Pharmaceuticals Inc: Rasio total nilai perusahaan marang pendapatan

Logo perusahaan publik ars-pharma.com (SPRY)

ARS Pharmaceuticals is attracting leading biochemists through the development of the innovative drug Neffy, utilizing an ambitious startup approach and RSUs for talent retention. The change in EV/Sales demonstrates the current market valuation, while the value of 2630.10 reflects this status. The business model ensures high scalability due to the low cost of mass-producing sprays, and the commercial launch of non-throat allergy treatments is driving rapid revenue growth.

ARS Pharmaceuticals Inc - Rasio nilai perusahaan marang pendapatan SPRY (periode 23.11.2025 - 20.11.2026)

ARS Pharmaceuticals Inc - rincian analitis lan metrik utama (SPRY)

Analisis wiwitan perusahaan:ars-pharma.com SPRY
Sampel barang ARS Pharmaceuticals, Inc.

This ratio relates the enterprise value, including debt and subtracting cash, to total sales. It determines the market value of one dollar of revenue, excluding the impact of the debt load. By analyzing the EV-to-revenue trend, an investor assesses the asset's fundamental resilience to market shocks. For ARS Pharmaceuticals (SPRY), this indicator reflects the capitalization of Neffy's potential as a unique emergency relief tool. The metric allows for an understanding of the extent to which the market overvalues the innovativeness of this adrenaline delivery system.

Analisis pesaing

HLN: Rasio nilai perusahaan marang pendapatan|Kenvue Corp (KVUE) - Rasio nilai perusahaan marang pendapatan|Verona Pharma PLC - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Jyong Biotech Ltd|Multiplikator EV/Sales Ligand Corp|Multiplikator EV/Sales AMRX|Rasio total nilai perusahaan marang pendapatan Perrigo Company plc|Multiplikator EV/Sales ALVO (Alvotech Biopharmaceuticals)|LQDA: Rasio nilai perusahaan marang pendapatan|Galapagos N.V. - Multiplikator EV/Sales|ANIP - Multiplikator EV/Sales|MNKD: Multiplikator EV/Sales|amphastar.com (AMPH) - Multiplikator EV/Sales|PCRX (Pacira Pharmaceuticals) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan Theravance Biopharma, Inc. (TBPH)|Nilai perusahaan marang pendapatan AQST (Aquestive Pharma)|SCPH - Multiplikator nilai perusahaan marang pendapatan|Multiplikator EV/Sales TECX (Tectonic Therapeutic, Inc.)|TNXP - Nilai perusahaan marang pendapatan|China SXT Pharmaceuticals, Inc. - Multiplikator EV/Sales|EPRX - Multiplikator EV/Sales|BHST: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan eXoZymes Inc (EXOZ)|ORMP (oramed.com) - Multiplikator EV/Sales|Rasio nilai perusahaan marang pendapatan ENTX (Entera Bio)|Rasio nilai perusahaan marang pendapatan MindWalk (HYFT)|Multiplikator EV/Sales ABVC BioPharma, Inc. (ABVC)|Rasio nilai perusahaan marang pendapatan Cumberland Corp CPIX|QNTM - Nilai perusahaan marang pendapatan|FGEN - Rasio nilai perusahaan marang pendapatan|TELO - Multiplikator EV/Sales|Rani Therapeutics Inc (RANI) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan SNYR|Rasio nilai perusahaan marang pendapatan Rallybio Corp|Rasio nilai perusahaan marang pendapatan LEXX|Multiplikator EV/Sales PULM|PTHL: Nilai perusahaan marang volume dodolan|Multiplikator EV/Sales APM (Aptorum Group Ltd)|LYRA - Nilai perusahaan marang pendapatan|Impact BioMedical Inc - Multiplikator EV/Sales|Nilai perusahaan marang volume dodolan TNFA|YCBD (cbdmd.com) - Nilai perusahaan marang pendapatan|painreform.com - Nilai bisnis marang pendapatan|Nilai perusahaan marang pendapatan CYTO|Rasio nilai perusahaan marang pendapatan LIPO|Rasio nilai perusahaan marang pendapatan optinose.com (OPTN)|PIRS (Pieris Pharma) - Nilai bisnis marang pendapatan|Rasio nilai perusahaan marang pendapatan Procaps Group S.A. PROC|Rasio total nilai perusahaan marang pendapatan petrospharma.com (PTPI)|QLI - Rasio nilai perusahaan marang pendapatan|Nilai bisnis marang pendapatan SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Rasio nilai perusahaan marang pendapatan